JP Patent

JP6710158B2 — Ａｍｇ４１６の製造方法

Assigned to Amgen Inc · Expires 2020-06-17 · 6y expired

What this patent protects

Patent listed against Parsabiv.

Drugs covered by this patent

Parsabiv (ETELCALCETIDE) · Kai Pharms Inc

Patent Metadata

Patent number: JP6710158B2
Jurisdiction: JP
Classification: —
Expires: 2020-06-17
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.